Abstract
SB8 is a biosimilar of the monoclonal anti-VEGF antibody bevacizumab and is approved in the EU for use in the same types of cancer as bevacizumab. SB8......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
